

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		SERIAL NO.	10/515,934
		FILING DATE	May 19, 2006
		APPLICANT	Mercep et al.
		GROUP	1614
		EXAMINER	A.M. Lewis
		ATTORNEY DOCKET NO.	PLP529USw

U.S. PATENT DOCUMENTS 1/08/2009

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1	3,773,940	11/20/1973	Schindler et al.			
	2	3,781,294	Dec. 25, 1973	Lombardino			
	3	3,859,439	01/07/1975	Blattner and Schindler			
	4	4,112,110	09/15/1978	Blattner			
	5	4,271,179	06/02/1981	van der Burg			
	6	4,267,190	05/12/1981	Cherkofsky et al.			
	7	4,267,184	05/12/1981	Cherkofsky et al.			
	8	7,312,203	12/25/2007	Mercep et al.			
	9	7,435,834	October 2008	Mercep et al.			
	10	US 2005/0148578	07/05/2005	Mercep et al.			

Continue on page _____

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	11	EP 0125484	11/21/1984	Ciba Geigy AG			
	12	EP 0357126	03/07/1990	Akzo N.V.			
	13	HR 20000310	Feb. 28, 2002	CROATIA			X
	14	WO 91/18885	Dec. 12, 1991	WIPO			
	15	WO 98/54186	12/03/1998	Akzo Nobel N.V.			
	16	WO 01/87890	Nov. 22, 2001	WIPO			
	17	WO 03/097648	11/27/2003	Pliva d.d.			

Continue on page _____

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

18	Badger et al. "Pharmacological profile of SB-203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function." <i>J. Pharmac. Env. Therap.</i> , 1996, 279(3):1453-1461.
19	Bennett et al. "Reaction of 5-acetyl-10, didehydro-5H-dibenz[b,f] azepine with pyrrole, N-methylpyrrole, imadazole and n-methylimidazole: cycloaddition versus Michael addition." <i>J. Heterocycl. Chem.</i> , 1994, 31:293-296.
20	Bresnihan. "Treatment with recombinant human interleukin-1 receptor antagonist (rhIL-1ra) in rheumatoid arthritis (RA); results of randomized double-blind, placebo-controlled multicenter trial." <i>Arthrit. Rheum.</i> , 1996, 39:73.
21	Carswell et al. "An endotoxin-induced serum factor that causes necrosis of tumors." <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 1975, 72:3666-3670.
22	Collier et al. "The abdominal constriction response and its suppression by analgesic drugs in the mouse." <i>Br. J. Pharmac. Chemother.</i> , 1968, 32:295-310
23	Dinarello. "An update on human interleukin-1: From molecular biology to clinical relevance." <i>J. Clinical Immunology</i> , 1985, 5:287.
24	Dinarello. "Interleukin-1." <i>Rev. Infect. Disease</i> , 1984, 6(1):51-95.
25	Elliott et al. "Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis." <i>The Lancet</i> , 1994, 344:1105-1110.
26	Fukawa et al. "A method for evaluating analgesic agents in rats." <i>J. Pharmacol. Meth.</i> , 1980, 4:251-259.
27	Funke et al. "Physico-chemical properties and stability of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1-dibenz[2,3:6,7]oxepino[4,5-c]pyrrolidine Maleate. <i>Arzheim-Forsch.</i> , 1190, 40:536-539.
28	Georgopoulos et al. "Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice." <i>J. Inflamm.</i> , 1996, 46:86-97.
29	Keffer, et al. "Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis." <i>EMBO J.</i> , 1991, 10:4025-4031.

/Amy Lewis/

11/08/2009

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.L./

	30	Mattioli and Ghia. "Omega-dialkylaminoalkyl ethers of phenyl-(5-substituted 1-phenyl-1H-pyrazol-4-yl)methanols with analgesic and anti-inflammatory activity." <i>J. Heterocyclic Chem.</i> , 1997, 34:963-968.
	31	Mori et al. "Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice." <i>J. Immunol.</i> , 1996, 157:3178-3182.
	32	Novacek et al. "Reaction of 8-chloro-10-phenylhydrazono-10, 11-dihydro-dibenzo[b,f]thepine with aromatic aldehydes." <i>Collection Czechoslov. Chem. Commun.</i> , 1976, Vol. 41, 785-787.
	33	Pfeffer et al. "Mice deficient for the 55kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to <i>L. monocytogenes</i> infection." <i>Cell</i> , 1993, 73:457-467.
	34	Schulz et al. "Synthese von 1,3a,3,12b-tetrahydro-dibenzo[b,f]-pyrazolo[3,4-d]azepin-Derivaten." <i>Z. Chem.</i> 1988, 28:181-182.
	35	Schweizer et al. "Combined automated writhing/motility test for testing analgesics." <i>Agents and Actions</i> , 1988, 23:29-31.
	36	Van Assche and Rutgeerts. "Anti-TNF agents in Crohn's disease." <i>Exp. Opin. Invest. Drugs</i> , 2000, 9:103-111.
	37	Wermuth et al. "Molecular Variations Based on Isosteric Replacements." <i>Practice of Medicinal Chemistry</i> , 1996, pages 203-237.

Continue on page _____

EXAMINER	/Amy Lewis/	DATE CONSIDERED
		11/08/2009

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.